An Open-Label, 2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1404 Administered to Healthy Male Subjects
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Lazuvapagon (Primary) ; Lazuvapagon (Primary)
- Indications Nocturia
- Focus Pharmacokinetics
- Sponsors Sanwa Kagaku Kenkyusho
- 12 Oct 2016 Status changed from recruiting to completed.
- 07 Sep 2016 New trial record